|Bid||35.08 x 1000000|
|Ask||35.32 x 1000000|
|Day's Range||35.22 - 35.99|
|52 Week Range||20.40 - 51.79|
|Beta (3Y Monthly)||0.94|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
How realistic is Canopy Growth's lofty CBD goal? Yahoo Finance's Zack Guzman and Brightfield Group Managing Director Bethany Gomez discuss.
Canopy growth stock plunges after the cannabis company missed earnings expectations. Yahoo Finance's Seana Smith along with MGO-ELLO Alliance CEO Evan Eneman discuss.
Canopy Growth stock took a tumble after the Canadian company reported sluggish marijuana sales. Canopy CEO Bruce Linton said in an interview that “massive” margins are coming.
Marijuana stocks have been a volatile but largely outperforming group in 2019. But an analyst warns that while some companies are living up to the hype, others have risen too far, too fast.
Canopy Growth and Cronos Group expressed reservations about Canada's THC limits on cannabis-infused edibles and beverages. Most marijuana stocks rose.
Several Wall Street analysts have come out bullish on cannabis stocks in recent months, but one analyst said Monday that Aurora Cannabis Inc (NYSE: ACB ) is the clear top choice in the sector. The Analyst ...
Powered by a deal with Corona-maker Constellation Brands Inc that has left it with $4.5 billion to invest, Canopy is in pole position to cash in on Canada's legalization of marijuana for recreational use as well as expectations that the United States may follow. Constellation is betting in part on the promise that federal legislation might eventually follow moves by state governments in the United States to legalize, opening the door to legal production countrywide, and there have been tentative signs that others may follow.
has a five-year track record of solid revenue growth, improved margins, and strong profitability. More recently, though, the stock is getting pulled into the ongoing trade war between the United States and China. Earnings per share increased 51% in fiscal 2018 (May) to $16.79 per diluted share.
Canopy Growth Corporation (NYSE: CGC) is adding to its production capacity, announcing Monday that it received a license for an outdoor cultivation site in Northern Saskatchewan. Canopy is projecting revenue generation from the rollout of the second phase of Canadian marijuana products in October. Canopy said it has several IP-protected pieces of equipment and processes to go along with its patents on vape production and extraction.
Are marijuana stocks on U.S. exchanges a good buy now? The marijuana industry gets a lot of hype, but look past the smoke and analyze pot stocks on their fundamentals and technicals.
Friday was a difficult day for cannabis companies after Canopy Growth Corp (NYSE: CGC )'s earnings report showed a quarter-over-quarter decline in Canadian recreational usage, CNBC's Jim Cramer said during ...
Sales are likely to fall short of expectations again unless products such as vape pens and marijuana-spiked beverages don’t provide a quick boost once they are approved for sale in Canada, according to BMO Capital Markets.
The cannabis company's revenue quadrupled, its net loss widened 500%, and its average selling price per gram declined 11% in its fiscal fourth quarter.
This was one of the most significant weeks for cannabis in recent history, as the U.S. House of Representatives voted in favor of an amendment that would stop the federal government and its agencies from interfering with legal cannabis programs, individuals and businesses in compliance with state, territorial or tribal cannabis laws. “Meanwhile, the cannabis industry isn’t waiting for regulators to catch up,” as proven by investments exceeding $1.3 billion through the first half of the year, Eneman said.
The Dow Jones Industrial Average ended down Friday, but held onto most of the week's gains following reports that President Donald Trump ordered, but then rescinded, an airstrike on military installations in Iran. Canopy Growth is Real Money's Stock of the Day. advanced following a report in The Wall Street Journal that the company was ready to buy healthcare payments group Equian LLC for around $3.2 billion.
Jim Cramer weighs in on the surges in gold and oil, Slack's first full day as a public company and Canopy Growth's earnings report.
Canopy Growth Corp (NYSE: CGC ) shares tanked Friday after the company’s fourth-quarter earnings report fell short of Wall Street expectations. Despite the mixed report, one analyst said Canopy is still ...